Last reviewed · How we verify
NCT05202067
Impact of Pharmaceutical Education on Medication Adherence
NA trial testing pharmaceutical education in Type 2 Diabetes in 103 participants. Completed in 30 December 2019.
30 June 2019
Quick facts
| Lead sponsor | Hospital Civil Juan I. Menchaca |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 103 |
| Start date | 1 January 2019 |
| Primary completion | 30 June 2019 |
| Estimated completion | 30 December 2019 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- pharmaceutical education
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Systemic Arterial Hypertension — all drugs for Systemic Arterial Hypertension →
- Medication Adherence — all drugs for Medication Adherence →
Sponsor
Hospital Civil Juan I. Menchaca
Who can join
Adults 18 to 60, any sex, with Type 2 Diabetes or Systemic Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose. To evaluate the impact of pharmaceutical education in patients with Type 2 Diabetes Mellitus and Systemic Arterial Hypertension on their medication adherence. Material and research methods. Randomized clinical trial with a control group with a duration of 6 months of follow-up. Patients with a diagnosis of Type 2 Diabetes Mellitus andWE Systemic Arterial Hypertension treated in the internal medicine outpatient of a school hospital will be included. Adherence to medication will be evaluated using Morisky's 8-item medication adherence scale. The investigators believe that Pharmaceutical education increases therapeutic adherence in patients with Type 2 Diabetes Mellitus and Systemic Arterial Hypertension.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of Pharmaceutical Education on Medication Adherence and Its Clinical Efficacy in Patients with Type 2 Diabetes and Systemic Arterial Hypertension.
Contreras-Vergara A, Sifuentes-Franco S, Haack S, Graciano-Machuca O, et al · · 2022 · cited 20× · PMID 35958890 · DOI 10.2147/ppa.s370323
Verify or expand the search:
- PubMed search for NCT05202067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Hospital Civil Juan I. Menchaca trials
Trials by the same sponsor.
- NCT04628117 — Effect of Oral Nutritional Supplementation on Oxidative Stress in Protein-energy Wasting Patients With Peritoneal Dialys · NA · unknown
- NCT03344549 — Effect of the Teleconsultation of Renal Nutrition on Renal Function and Glycemic Control in Patients With DKD · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05202067 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Civil Juan I. Menchaca
- Last refreshed: 3 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing